Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Chronic Lymphocytic Leukemia | Research

Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort

Authors: Salem H. Alshemmari, Ahmad AlSarraf, Andy Kaempf, Alexey V. Danilov

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

In chronic lymphocytic leukaemia (CLL), comorbidities assessed by the CLL comorbidity index (CLL-CI) have been associated with outcomes in Western cohorts. We conducted a retrospective analysis of an unselected Middle Eastern cohort of newly diagnosed CLL patients seen at the Kuwait Cancer Control Center (n = 300). Compared to Western studies, these Middle Eastern patients were diagnosed at a younger age (median of 59) and had a higher comorbidity burden (69% non-low risk CLL-CI). A higher CLL-CI score was independently associated with significantly shorter event-free survival and greater risk of death. Our analysis demonstrates that CLL-CI is a valuable tool for comorbidity assessment and prognostic influence in (relatively young) Middle Eastern CLL patients.
Literature
1.
go back to reference Hallek M, Eichhorst B, Catovsky D. Chronic lymphocytic leukemia. Cham: Springer International Publishing; 2019. Hallek M, Eichhorst B, Catovsky D. Chronic lymphocytic leukemia. Cham: Springer International Publishing; 2019.
3.
7.
go back to reference Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and Rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42. https://doi.org/10.1016/S1470-2045(16)30051-1.CrossRefPubMed Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and Rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42. https://​doi.​org/​10.​1016/​S1470-2045(16)30051-1.CrossRefPubMed
13.
go back to reference ALNohair S. Obesity in Gulf Countries. Int J Health Sci (Qassim). 2014;8:79–83.PubMed ALNohair S. Obesity in Gulf Countries. Int J Health Sci (Qassim). 2014;8:79–83.PubMed
14.
go back to reference Meo SA, Usmani AM, Qalbani E. Prevalence of type 2 diabetes in the arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017;21:1303–12.PubMed Meo SA, Usmani AM, Qalbani E. Prevalence of type 2 diabetes in the arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017;21:1303–12.PubMed
Metadata
Title
Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort
Authors
Salem H. Alshemmari
Ahmad AlSarraf
Andy Kaempf
Alexey V. Danilov
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12343-1

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine